These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 30367445)

  • 1. Cell-free DNA in cancer: current insights.
    Fettke H; Kwan EM; Azad AA
    Cell Oncol (Dordr); 2019 Feb; 42(1):13-28. PubMed ID: 30367445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges.
    García-Pardo M; Makarem M; Li JJN; Kelly D; Leighl NB
    Br J Cancer; 2022 Sep; 127(4):592-602. PubMed ID: 35347327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-free DNA as a post-treatment surveillance strategy: current status.
    Burgener JM; Rostami A; De Carvalho DD; Bratman SV
    Semin Oncol; 2017 Oct; 44(5):330-346. PubMed ID: 29580435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements.
    Tuaeva NO; Falzone L; Porozov YB; Nosyrev AE; Trukhan VM; Kovatsi L; Spandidos DA; Drakoulis N; Kalogeraki A; Mamoulakis C; Tzanakakis G; Libra M; Tsatsakis A
    Cells; 2019 Oct; 8(10):. PubMed ID: 31615102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cell-free tumor DNA analysis in pediatric cancers.
    Andersson D; Fagman H; Dalin MG; Ståhlberg A
    Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid biopsy and minimal residual disease - latest advances and implications for cure.
    Pantel K; Alix-Panabières C
    Nat Rev Clin Oncol; 2019 Jul; 16(7):409-424. PubMed ID: 30796368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bridging biological cfDNA features and machine learning approaches.
    Moser T; Kühberger S; Lazzeri I; Vlachos G; Heitzer E
    Trends Genet; 2023 Apr; 39(4):285-307. PubMed ID: 36792446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
    Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
    Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    Haupts A; Roth W; Hartmann N
    Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relevance of liquid biopsy in surgical oncology: The application of perioperative circulating nucleic acid dynamics in improving patient outcomes.
    Jordan PR; O'Leary DP; Fleming CA; Wang J; Redmond HP
    Surgeon; 2022 Aug; 20(4):e163-e173. PubMed ID: 34362650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA: current challenges for clinical utility.
    Dang DK; Park BH
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.